CBD cigarettes from Heimat in clinical trial: Less medication, more well-being? Results of the pilot study at the University Psychiatric Clinics Basel.
Two studies conducted at the University Psychiatric Clinics Basel and published in the renowned journal Frontiers in Psychiatry published Swiss studies have for the first time systematically examined the use of CBD cigarettes in a psychiatric context At the center: a freely available natural product – the CBD cigarettes from Heimat , made in Switzerland.
Hemp cigarettes in everyday clinical practice: indications of reduced medication requirements
In an open pilot study, researchers followed patients diagnosed with psychosis for 25 weeks. The aim was to determine under real-life conditions whether the use of Home CBD cigarettes positive effect on the use of antipsychotic medication, subjective well-being, and general symptoms. Participants were divided into two groups:
- Group A: CBD cigarettes with <1% THC
- Group B: Placebo cigarettes made from pure tobacco
The results: In the In the CBD group, total antipsychotic consumption was lower , accompanied by a significant increase in perceived well-being:
"The main group effects (...) were higher subjective well-being and lower total antipsychotic medication use in the CBD group." (Frontiers in Psychiatry, https://doi.org/10.3389/fpsyt.2021.736822 )
Additional observations: Reduction in substance use and stabilization
A complementary case study (Frontiers in Psychiatry, https://doi.org/10.3389/fpsyt.2021.712110 ) documents the course of a patient with long-term multiple addiction to highly stressful substances. During the regular use of Home CBD cigarettes A noticeable reduction in addictive behavior and increased psychological stability were observed. This enabled, for the first time, an in-depth therapeutic approach.
These observations underline the potential of CBD products as low-threshold, accepted support in mental health care – an approach that opens up new perspectives both medically and socially.
CBD cigarettes as a complementary measure in therapy?
The studies deliberately used a Commercially available product : CBD cigarettes from Heimat. These are considered a tobacco substitute in Switzerland, not a medicine – and are therefore legally available without a prescription. The results suggest that CBD cigarettes as a potential complement to conventional therapy in psychiatric care. However, larger controlled studies are needed to conclusively evaluate these potential effects.
Independent research – transparent and approved by an ethics committee
The studies were conducted independently, with the approval of the Ethics Committee Northwestern and Central Switzerland . The brand Hometown provided the product examined, but was not involved in planning, implementation or evaluation – an important quality feature for the scientific validity of the results.
